{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:58:38Z","timestamp":1791979118860,"version":"4.4.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1002744"],"award-info":[{"award-number":["OPP1002744"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) is a leading cause of viral pneumonia and bronchiolitis during the first 6 months of life. Placentally transferred antibodies can prevent severe RSV illness, and maternal immunization may reduce illness in young infants. Identification of protective antibody levels facilitates the advancement of vaccine candidates and maternal immunization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a nested case-control study with 587 Malian mother\u2013infant pairs, followed from birth to age 6 months. RSV cases were infants who developed influenza-like illness (ILI) or pneumonia and were RSV-positive by polymerase chain reaction. Cases were matched to healthy controls and RSV-negative ILI controls. RSV-A and RSV-B neutralizing antibodies were measured in maternal, cord blood, and infant sera at age 3 and 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Maternal antibodies were efficiently transferred to infants. Maternal and infant RSV titers were strongly correlated. Infant antibody titers against RSV-A were 3 times higher than those against RSV-B. At birth, infants who remained healthy had significantly higher RSV-A and RSV-B titers compared with infants who subsequently contracted RSV. RSV-A inhibitory concentration (IC)80 titer &amp;gt;239 or RSV-B titer &amp;gt;60 at birth was significantly associated with being a healthy control compared with an RSV case within the first 3 months of life. RSV-A IC80 titers in cord blood were associated with decreased episodes of pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Maternally acquired RSV antibodies were associated with protection of infants against community-detected cases of RSV-ILI and pneumonia. RSV titers in cord blood can predict whether an infant will be infected with RSV or remain uninfected.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa648","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T00:22:17Z","timestamp":1590193337000},"page":"e4421-e4427","source":"Crossref","is-referenced-by-count":77,"title":["Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of Life"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6503-6459","authenticated-orcid":false,"given":"Andrea G","family":"Buchwald","sequence":"first","affiliation":[{"name":"Department of Environmental and Occupational Health, Colorado School of Public Health, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barney S","family":"Graham","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awa","family":"Traore","sequence":"additional","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins\u2013Mali, Bamako, Mali"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadima Cheick","family":"Haidara","sequence":"additional","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins\u2013Mali, Bamako, Mali"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Chen","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Morabito","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob C","family":"Lin","sequence":"additional","affiliation":[{"name":"Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samba O","family":"Sow","sequence":"additional","affiliation":[{"name":"Centre pour le D\u00e9veloppement des Vaccins\u2013Mali, Bamako, Mali"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron M","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela F","family":"Pasetti","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagritos D","family":"Tapia","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"2021121011154775600_CIT0001","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1067\/S0022-3476(03)00510-9","article-title":"Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000","volume":"143","author":"Leader","year":"2003","journal-title":"J Pediatr"},{"key":"2021121011154775600_CIT0002","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(13)60222-6","article-title":"Global burden of childhood pneumonia and diarrhoea","volume":"381","author":"Walker","year":"2013","journal-title":"Lancet"},{"key":"2021121011154775600_CIT0003","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/INF.0b013e3182184ae7","article-title":"Epidemiology and prevention of respiratory syncytial virus infections among infants and young children","volume":"30","author":"Langley","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2021121011154775600_CIT0004","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/infdis\/jiu316","article-title":"Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh","volume":"210","author":"Chu","year":"2014","journal-title":"J Infect Dis"},{"key":"2021121011154775600_CIT0005","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/jmv.10148","article-title":"Prevalence of respiratory syncytial virus IgG antibodies in infants living in a rural area of Mozambique","volume":"67","author":"Roca","year":"2002","journal-title":"J Med Virol"},{"key":"2021121011154775600_CIT0006","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1016\/S0264-410X(03)00355-4","article-title":"Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies","volume":"21","author":"Piedra","year":"2003","journal-title":"Vaccine"},{"key":"2021121011154775600_CIT0007","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/INF.0b013e31815ac585","article-title":"The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease","volume":"27","author":"Eick","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"2021121011154775600_CIT0008","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaci.2008.10.043","article-title":"Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze","volume":"123","author":"Stensballe","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"2021121011154775600_CIT0009","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0022-3476(81)80829-3","article-title":"Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level","volume":"98","author":"Glezen","year":"1981","journal-title":"J Pediatr"},{"key":"2021121011154775600_CIT0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/infdis\/134.3.211","article-title":"Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus","volume":"134","author":"Lamprecht","year":"1976","journal-title":"J Infect Dis"},{"key":"2021121011154775600_CIT0011","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/oxfordjournals.aje.a115826","article-title":"Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life","volume":"133","author":"Holberg","year":"1991","journal-title":"Am J Epidemiol"},{"key":"2021121011154775600_CIT0012","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jcv.2017.08.017","article-title":"Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal","volume":"95","author":"Chu","year":"2017","journal-title":"J Clin Virol"},{"key":"2021121011154775600_CIT0013","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S1473-3099(16)30054-8","article-title":"Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2021121011154775600_CIT0014","first-page":"6","volume-title":"Revised WHO classification and treatment of childhood pneumonia at health facilities","year":"2014"},{"key":"2021121011154775600_CIT0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/cid\/ciz157","article-title":"Epidemiology, risk factors, and outcomes of respiratory syncytial virus infections in newborns in Bamako, Mali","volume":"70","author":"Buchwald","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021121011154775600_CIT0016","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/jmv.1890070403","article-title":"Maternal antibody and respiratory syncytial virus infection in infancy","volume":"7","author":"Ogilvie","year":"1981","journal-title":"J Med Virol"},{"key":"2021121011154775600_CIT0017","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/adc.2002.017780","article-title":"The progression of maternal RSV antibodies in the offspring","volume":"89","author":"Hacimustafaoglu","year":"2004","journal-title":"Arch Dis Child"},{"key":"2021121011154775600_CIT0018","doi-asserted-by":"crossref","first-page":"e0166706","DOI":"10.1371\/journal.pone.0166706","article-title":"Absence of association between cord specific antibody levels and severe respiratory syncytial virus (RSV) disease in early infants: a case control study from coastal Kenya","volume":"11","author":"Nyiro","year":"2016","journal-title":"PLoS One"},{"key":"2021121011154775600_CIT0019","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1542\/peds.109.2.210","article-title":"Risk factors for severe respiratory syncytial virus infection among Alaska native children","volume":"109","author":"Bulkow","year":"2002","journal-title":"Pediatrics"},{"key":"2021121011154775600_CIT0020","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/infdis\/jiv263","article-title":"Frequent asymptomatic respiratory syncytial virus infections during an epidemic in a rural Kenyan household cohort","volume":"212","author":"Munywoki","year":"2015","journal-title":"J Infect Dis"},{"key":"2021121011154775600_CIT0021","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1128\/jcm.24.5.894-898.1986","article-title":"Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection","volume":"24","author":"Murphy","year":"1986","journal-title":"J Clin Microbiol"},{"key":"2021121011154775600_CIT0022","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1542\/peds.111.1.218","article-title":"Why no effect of maternal respiratory syncytial virus-neutralizing antibody?","volume":"111","author":"Munoz","year":"2003","journal-title":"Pediatrics"},{"key":"2021121011154775600_CIT0023","doi-asserted-by":"crossref","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Trans Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa648\/33673024\/ciaa648.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e4421\/41607717\/ciaa648.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e4421\/41607717\/ciaa648.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T06:25:40Z","timestamp":1639117540000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/11\/e4421\/5848236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":23,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,5,28]]},"published-print":{"date-parts":[[2021,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa648","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2020,5,28]]}}}